Form D · Biotechnology
Cerecin Inc.
Denver, CO · CIK 0001293610
Offering snapshot reported Jun 25, 2024 · SEC filing
- Reported sold
- $3.74M Offering amount: $7M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 25, 2024 | Initial | $3,740,000 | No comparison | 10 | SEC filing |
| Aug 18, 2022 | Initial | $7,220,002 | No comparison | 1 | SEC filing |
| Sep 29, 2021 | Initial | $10,000,001 | No comparison | 3 | SEC filing |
| Feb 5, 2021 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Mar 26, 2018 | Initial | $17,639,537 | No comparison | 2 | SEC filing |
| Jan 21, 2014 | Amendment | $84,081,610 | $5,000,000vs Oct 25, 2013 | 2 | SEC filing |
| Oct 25, 2013 | Amendment | $79,081,610 | $60,684,314vs Jul 27, 2012 | 2 | SEC filing |
| May 7, 2013 | Amendment | $69,081,610 | $35,000,000vs Oct 12, 2012 | 2 | SEC filing |
| Oct 12, 2012 | Amendment | $34,081,610 | $15,684,314vs Jul 27, 2012 | 2 | SEC filing |
| Jul 27, 2012 | Initial | $18,397,296 | No comparison | 2 | SEC filing |
| May 24, 2012 | Initial | $4,882,125 | No comparison | 1 | SEC filing |
| May 24, 2012 | Initial | $3,900,787 | No comparison | 1 | SEC filing |
| Dec 21, 2010 | Initial | $11,000,000 | No comparison | 3 | SEC filing |
| Mar 15, 2010 | Initial | $9,487,313 | No comparison | 4 | SEC filing |
| Apr 23, 2009 | Amendment | $26,051,995 | No comparison | Not reported | SEC filing |
| Dec 5, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 7, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 27, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516835
Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion
Source: Form D, filed Jun 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Evan Ballantyne | Executive |
| Greg Behar | Director |
| Luis Cantarell | Director |
| Samuel T. Henderson | Executive |
| Gary Hooper | Director |
| Gregory J. Kading | Executive |
| Ki Kab Kim | Director |
| Jerris Knaisch | Executive |
| Holger Kunze | Executive |
| Claude Nash | Director |
| Steve Orndorff | Director, Executive |
| Rahul Rajashekar | Director |
| Wolfgang Reichenberger | Director |
| Robert Schier | Director |
| Dilpreet Singh | Executive |
| Charles Stacey | Director, Executive |
| Nicholas Charles Stacey | Director, Executive |
| Sven Thormahlen | Director |
| Milan Vinnola | Executive |
| Gurpreet Singh Vohra | Director |
| Gunnar Weikert | Director |
| Thomas Werner | Director |
| Hans Juergen Woerle | Director |
| Hans Jurgen Woerle | Director |
| Joseph S. Zakrzewski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
44 Cook Street Suite 100 71
Denver, CO, 80206
Denver, CO, 80206